GeoVax Labs, Inc. (Nasdaq: GOVX) has welcomed the launch of a new global mpox vaccine stockpile, a move that could significantly enhance the world's ability to respond to future outbreaks. The stockpile, announced by the World Health Organization (WHO) on September 2, is funded by Gavi, the Vaccine Alliance, and coordinated through the International Coordinating Group (ICG) on Vaccine Provision, which includes partners such as UNICEF, Médecins Sans Frontières, and the International Federation of Red Cross and Red Crescent Societies. It is scheduled to begin operations later this month, establishing a long-term mechanism for equitable vaccine access during mpox outbreaks.
David A. Dodd, Chairman and CEO of GeoVax, emphasized the importance of this initiative: "Establishing a dedicated global mpox vaccine stockpile is an important step forward in moving from reactive outbreak response toward sustained preparedness. Equitable access requires more than having vaccines available after an outbreak begins. It requires durable procurement infrastructure, sufficient vaccine supply, and the ability to rapidly deliver vaccine protection where it is needed." He also noted that GeoVax looks forward to engaging with global health partners as its mpox vaccine candidate, GEO-MVA, advances toward pivotal Phase 3 evaluation.
The stockpile builds on the Access and Allocation Mechanism used during the 2024 mpox public health emergency, addressing persistent barriers to vaccine access. WHO has identified securing a robust product mix of vaccines and supplies and supporting market-shaping efforts to promote longer-term sustainable access as strategic objectives. This underscores the importance of reliable and diversified vaccine supply in global preparedness.
GeoVax is developing GEO-MVA, a Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox and smallpox prevention. The company has completed key manufacturing, regulatory, clinical, and preclinical milestones to support the planned initiation of its pivotal Phase 3 immune-bridging study in the fourth quarter of 2026. Manufacturing readiness is confirmed, with GMP clinical product already produced and released for the study. Regulatory alignment with the European Medicines Agency supports an expedited immune-bridging pathway comparing GEO-MVA to the licensed MVA-BN vaccine. Clinical readiness is advancing, with CRO engagement and site identification underway for the approximately 500-participant study. Preclinical studies have generated orthopoxvirus-specific immune responses and neutralizing-antibody data supporting the immune-bridging strategy.
As the new stockpile infrastructure develops, GeoVax believes additional qualified MVA vaccine sources could help expand supply availability and manufacturing capacity. The company is engaging government agencies and international preparedness organizations regarding future procurement requirements and the potential role of GEO-MVA as an additional source of MVA vaccine supply. Dodd added, "Creating a sustainable procurement mechanism is an important part of preparedness, but preparedness also requires sufficient and reliable vaccine supply. Our objective with GEO-MVA is to contribute a reliable additional source of MVA vaccine capacity that can strengthen global supply resilience and provide governments and international health organizations with greater supply flexibility."
Beyond GEO-MVA, GeoVax is pursuing next-generation MVA technologies, including MVA-X for single-dose protection, continuous-cell-line manufacturing for scalable production, and microarray-based delivery technologies to simplify administration. These efforts aim to address barriers to global vaccine access and deployment.
"The launch of this global stockpile represents a significant advance in the infrastructure for equitable mpox vaccine access and outbreak response," Dodd said. "The next challenge is ensuring that the vaccines supporting that stockpile can be manufactured at scale and deployed as efficiently and broadly as possible. Our longer-term MVA strategy is focused on that entire continuum."
As GEO-MVA progresses toward pivotal Phase 3 evaluation, GeoVax looks forward to working with Gavi, WHO, the ICG, and other international health organizations to expand sustainable and equitable access to mpox vaccines worldwide.
